BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10569455)

  • 1. The effect of maternal age, parity, and fetal sex on the amniotic fluid and maternal serum levels of CA 125, CA 19.9, CA 15.3, and CEA.
    Tayyar M; Tutus A
    Int J Fertil Womens Med; 1999; 44(5):256-9. PubMed ID: 10569455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of CA 72.4 in maternal serum and amniotic fluid.
    Tayyar M; Tutus A
    J Perinat Med; 1998; 26(5):400-3. PubMed ID: 10027137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study.
    Ercan Ş; Kaymaz Ö; Yücel N; Orçun A
    Arch Gynecol Obstet; 2012 Mar; 285(3):579-84. PubMed ID: 21792548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal serum and umbilical cord tumor marker levels at term pregnancy.
    Kiran G; Kiran H; Guler FI; Ekerbicer HC; Kilinc M
    Acta Obstet Gynecol Scand; 2005 Jan; 84(1):85-9. PubMed ID: 15603573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9, and CA 15-3 levels in differential diagnosis of ascites etiology.
    Sari R; Yildirim B; Sevinc A; Bahceci F; Hilmioglu F
    Hepatogastroenterology; 2001; 48(42):1616-21. PubMed ID: 11813585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A; Guven S; Guven ES; Kucukali T
    Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
    Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
    Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation.
    Pissaia A; Bernard D; Scatton O; Soubrane O; Conti F; Calmus Y
    Transplant Proc; 2009 Mar; 41(2):682-4. PubMed ID: 19328956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast.
    Lee A; Kim Y; Han K; Kang CS; Jeon HM; Shim SI
    Arch Pathol Lab Med; 2004 Nov; 128(11):1251-6. PubMed ID: 15508191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of tumour markers in molar pregnancy.
    Hegab HM; Schindler AE; Rizk M; Ramadan M
    Arch Gynecol Obstet; 2003 Aug; 268(3):151-4. PubMed ID: 12942241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer markers during normal pregnancy.
    Botsis D; Sarandakou A; Kassanos D; Kontoravdis A; Rizos D; Protonotariou E; Phocas I; Creatsas G
    Anticancer Res; 1999; 19(4C):3539-41. PubMed ID: 10629649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of tumor markers in chronic hemodialysis patients.
    Tzitzikos G; Saridi M; Filippopoulou T; Makri A; Goulioti A; Stavropoulos T; Stamatiou K
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):50-3. PubMed ID: 20061692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Beta-HCG concentration in maternal serum and in amniotic fluid of patients in labor with physiologic pregnancies].
    Kontoravdis VA; Kassanos D; Souchleri-Foka I; Chryssikopoulos A
    Zentralbl Gynakol; 1988; 110(8):494-500. PubMed ID: 2456648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of tumor markers in gestational trophoblastic diseases.
    Ahmad AE; Dehaghani AS; Shaker M; Fattahi MJ
    J Reprod Med; 2008 Dec; 53(12):930-4. PubMed ID: 19160651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue polypeptide specific antigen (TPS) throughout normal pregnancy.
    Kassanos D; Botsis D; Rizos D; Kontoravdis A; Sikiotis K; Phocas I; Sarandakou A; Creatsas G
    Anticancer Res; 2000; 20(3B):2129-31. PubMed ID: 10928165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amniotic fluid levels of CA 19.9 and CA 15.3 in normal and Down's syndrome pregnancies.
    Noci I; Borri P; Biagiotti R; Cariati E; Branconi F; Torricelli F; Cappelli G; D'Agata A
    J Perinat Med; 1995; 23(3):237-41. PubMed ID: 8568617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of serum tumour markers concentrations in patients with homozygous beta-thalassaemia in relation to demographical, clinical and biochemical parameters.
    Christoforidis A; Lefkou E; Vlachaki E; Perifanis V; Tsatra I; Dogramatzi F; Athanassiou-Metaxa M
    Ann Hematol; 2007 Nov; 86(11):837-41. PubMed ID: 17668208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances regarding tumor markers in bladder cancer].
    Moreno Sierra J; Chicharro Almarza GJ; Torronteras Santiago JM; Ortega Heredia MD; Maestro de las Casas ML; Silmi Moyano A; Resel Estévez L
    Actas Urol Esp; 1997 Mar; 21(3):195-205. PubMed ID: 9324884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.